Artelo Biosciences Ownership
| ARTL Stock | USD 1.10 0.01 0.90% |
Shares in Circulation | First Issued 2013-12-31 | Previous Quarter 3.2 M | Current Value 3.2 M | Avarage Shares Outstanding 2.1 M | Quarterly Volatility 4.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Artelo |
Artelo Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 0.56. Some equities with similar Price to Book (P/B) outperform the market in the long run. Artelo Biosciences recorded a loss per share of 2.87. The entity last dividend was issued on the 21st of June 2019. The firm had 1:15 split on the 10th of August 2022. Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California. Artelo Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. For more info on Artelo Biosciences please contact Gregory MBA at 858 925 7049 or go to https://www.artelobio.com.Besides selling stocks to institutional investors, Artelo Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Artelo Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Artelo Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Artelo Biosciences Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of Artelo Biosciences are currently held by insiders. Unlike Artelo Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Artelo Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Artelo Biosciences' insider trades
Artelo Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Artelo Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Artelo Biosciences backward and forwards among themselves. Artelo Biosciences' institutional investor refers to the entity that pools money to purchase Artelo Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 17.4 K | Tower Research Capital Llc | 2024-06-30 | 5.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 40.0 | Bank Of America Corp | 2024-06-30 | 26.0 | Rothschild Investment, Llc | 2024-09-30 | 8.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Goss Wealth Management Llc | 2024-06-30 | 0.0 | Citigroup Inc | 2024-09-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 |
Artelo Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Artelo Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Artelo Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Artelo Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Artelo Biosciences Outstanding Bonds
Artelo Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Artelo Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Artelo bonds can be classified according to their maturity, which is the date when Artelo Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artelo Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.87) | Return On Assets (0.54) | Return On Equity (0.89) |
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Artelo Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.